Related Experiment Video
Updated: Jun 10, 2026

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Angiotensinogen gene polymorphism in acute myocardial infarction patients
Sounira Mehri1, Sinda Mahjoub, Abdeljelil Farhati
1Laboratoire de Biochimie 'UR Human Nutrition & Metabolic Disorders', Faculté de Médecine, Monastir, Tunisie, Unité de Recherche 'Epidémiologie Génétique et Moléculaire', Faculté de Médecine de Tunis, Tunisie.
Introduction:
The objective of the study was to explore the role of a genetic variant of angiotensinogen (AGT), M235T, as an independent risk factor for acute myocardial infarction (AMI) and to investigate the possible association with the severity of coronary artery disease (CAD), estimated on the basis of the number of coronary stenoses and critical arterial occlusions.
Patients And Methods:
123 AMI patients were compared to 144 healthy controls. AGT genotypes were determined by PCR.
Results:
A significant association was found between AGT M235T polymorphism and AMI (p = .021). By logistic regression, the TT genotype appeared to confer 1.9-fold increased risk for AMI in both the univariate and the multivariate model. The frequencies of the TT genotype and T allele increased with the number of stenoses in coronary vessels. Moreover, the TT genotype and the T allele were more frequent in the subgroup of patients with stenoses in at least four coronary vessels than in other patients, including subjects with one- to three-vessel disease. Furthermore, the TT genotype and the T allele were significantly more frequent in patients with critical arterial occlusions (> 90%) than in subjects without critical stenoses.
Conclusions:
The AGT M235T polymorphism associates with AMI risk and influences CAD severity.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Pharmacogenomics: Identification of New Drug Targets
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
